WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Halozyme Therapeutics earnings were $595.5M for the trailing 12 months ending Sep 30, 2025, with 59.3% growth year over year. The latest HALO earnings report on Sep 30, 2025 announced Q3 2025 earnings of $175.2M, up 6.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HALO reported annual earnings of $444.1M, with 57.7% growth. The next HALO earnings date is Feb 24, 2026.

HALO past earnings growth

How has HALO's earnings growth performed historically?

Company
59.28%
Industry
64.12%
Market
53.52%
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HALO's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HALO earnings history

Current Revenue
$1.2B
Current Earnings
$595.5M
Current Profit Margin
47.9%

HALO Return on Equity

Current Company
141.6%
Current Industry
-21.2%
Current Market
35.1%
HALO's Return on Equity (141.6%)... subscribe to Premium to read more.
High Return on Equity Performance

HALO Return on Assets

Current Company
27.9%
Current Industry
-8.8%
HALO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when HALO announces earnings.

HALO Return on Capital Employed

Current Company
55.18%
Current Industry
-3.5%
HALO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HALO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
HALO$845.48M$595.49M+93.56%$4.89
AXSM-$211.35M-$229.53MN/A-$4.67
ABVXN/AN/AN/AN/A
CYTK-$702.05M-$751.94MN/A-$6.29
ARWR$133.08M-$1.63MN/A-$0.01
View Top Biotech Stocks

HALO earnings dates

Next earnings date
Feb 24, 2026

Halozyme Therapeutics Earnings Reports & History FAQ

What were Halozyme Therapeutics's earnings last quarter?

On HALO's earnings call on Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q3 2025 earnings per share (EPS) of $1.49, up 37.96% year over year. Total HALO earnings for the quarter were $175.23 million. In the same quarter last year, Halozyme Therapeutics's earnings per share (EPS) was $1.08.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.

When does Halozyme Therapeutics report earnings?

The next HALO earnings call is Invalid Date. Add HALO to your watchlist to be reminded of Halozyme Therapeutics's next earnings date.

Is Halozyme Therapeutics profitable or losing money?

As of the last Halozyme Therapeutics earnings report, Halozyme Therapeutics is currently profitable. Halozyme Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $595.49 million, a 51.73% increase year over year.

What was HALO's earnings growth in the past year?

As of Halozyme Therapeutics's earnings date in Invalid Date, Halozyme Therapeutics's earnings has grown 59.28% year over year. This is 4.84 percentage points lower than the US Biotechnology industry earnings growth rate of 64.12%. HALO earnings in the past year totalled $595.49 million.

What are Halozyme Therapeutics's earnings expectations?

The current EPS estimate for Halozyme Therapeutics's earnings report in Invalid Date is $1.90.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.